TIME-DEPENDENT CHANGES IN PLASMA GHRELIN AND ANGIOTENSIN II LEVELS IN THE DIABETIC NEPHROPATHY MODEL

被引:0
作者
Gul, Cihan [1 ]
Kelle, Mustafa [2 ]
Baylan, Mukadder [2 ]
Yokus, Beran [3 ]
Tasdemir, Ezel [4 ]
机构
[1] Batman Univ, Hlth Serv Vocat Sch, Dept Hlth Care Serv, TR-72060 Batman, Turkey
[2] Dicle Univ, Fac Med, Dept Physiol, Diyarbakir, Turkey
[3] Dicle Univ, Fac Vet, Dept Biochem, Diyarbakir, Turkey
[4] Med Pk Hosp, Internal Med Clin, Antalya, Turkey
来源
FRESENIUS ENVIRONMENTAL BULLETIN | 2021年 / 30卷 / 01期
关键词
Ghrelin; Nephropathy; Angiotensin II; Diabetes; Streptozotocin; BIOLOGICAL-ACTIVITY; ACYLATED PEPTIDE; HYPERTENSION; EXPRESSION; PREVENTION; RECEPTORS; INSULIN; SYSTEM; RATS;
D O I
暂无
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Ghrelin is an appetite-enhancing anabolic hormone secreted from the stomach. Angiotensin II maintains sodium and potassium levels in body fluids and plays a very important role in the regulation of arterial blood pressure. Although their relationship with Type 2 diabetes and complications have been reported, their role in diabetic nephropathy is not fully understood. We investigated time dependent possible changes in plasma ghrelin and angiotensin II levels during the development and progression of diabetic nephropathy in experimental diabetic rat model. Adult 63 male Wistar Albino rats were randomly divided into 9 groups as 4 control (C1-C4), 4 diabetic (D1-D4) and one treatment (T) group. Group D1, sacrificed by cardiac puncture one week after diabetes, group D2 three weeks later, group D3 six weeks later, and groups D4 and T eight weeks later. Antidiabetic treatment was not administered to the D1-D4 group diabetic rats. Group T diabetic rats were treated with antidiabetic metformin (100 mg / kg / day) for 8 weeks. A single dose of 35 mg / kg intraperitoneal streptozotocin was administered to the rats to induce diabetes. Significant differences were found between the D4 and C4 groups in body weight, plasma glucose, ghrelin and angiotensin II, serum and urine creatinine levels. While there was a linear (positive) relationship between plasma ghrelin levels of all rats and urinary creatinine and creatinine clearance and body weight, negative correlations were found between plasma ghrelin and angiotensin II levels and fasting blood glucose levels of all rats. During the progression of diabetes and the development of diabetes-related nephropathy, plasma angiotensin and serum creatinine levels increased, while plasma ghrelin levels decreased over time. Therefore, it was concluded that changes in plasma ghrelin and angiotensin II levels in diabetic rats may be associated with the pathogenesis of diabetic nephropathy.
引用
收藏
页码:747 / 757
页数:11
相关论文
共 29 条
[11]   Intrarenal ghrelin receptor inhibition ameliorates angiotensin II-dependent hypertension in rats [J].
Kemp, Brandon A. ;
Howell, Nancy L. ;
Padia, Shetal H. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 315 (04) :F1058-F1066
[12]   Ghrelin is a growth-hormone-releasing acylated peptide from stomach [J].
Kojima, M ;
Hosoda, H ;
Date, Y ;
Nakazato, M ;
Matsuo, H ;
Kangawa, K .
NATURE, 1999, 402 (6762) :656-660
[13]   Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor [J].
Kojima, M ;
Hosoda, H ;
Matsuo, H ;
Kangawa, K .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2001, 12 (03) :118-122
[14]   The NPY/AgRP neuron and energy homeostasis [J].
Morton, GJ ;
Schwartz, MW .
INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (Suppl 5) :S56-S62
[15]   Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure [J].
Nagaya, N ;
Kangawa, K .
REGULATORY PEPTIDES, 2003, 114 (2-3) :71-77
[16]   Growth hormone secretagogue binding sites in peripheral human tissues [J].
Papotti, M ;
Ghè, C ;
Cassoni, P ;
Catapano, F ;
Deghenghi, R ;
Ghigo, E ;
Muccioli, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3803-3807
[17]   Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes [J].
Pöykkö, SM ;
Kellokoski, E ;
Hörkkö, S ;
Kauma, H ;
Kesäniemi, YA ;
Ukkola, O .
DIABETES, 2003, 52 (10) :2546-2553
[18]   Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes [J].
Remuzzi, G ;
Benigni, A ;
Remuzzi, A .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (02) :288-296
[19]   Renoprotective effects of adding angootensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy - A randomized double-blind crossover trial [J].
Rossing, K ;
Jacobsen, P ;
Pietraszek, L ;
Parving, HH .
DIABETES CARE, 2003, 26 (08) :2268-2274
[20]   Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion [J].
Shiiya, T ;
Nakazato, M ;
Mizuta, M ;
Date, Y ;
Mondal, MS ;
Tanaka, M ;
Nozoe, SI ;
Hosoda, H ;
Kangawa, K ;
Matsukura, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :240-244